Chimerix to Report Third Quarter 2020 Financial Results and Provide an Operational Update on November 5, 2020
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 6085937. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the
About Chimerix
DSTAT is a potential first-in-class glycosaminoglycan compound derived from porcine heparin that, compared to commercially available forms of heparin, may be dosed at higher levels without associated bleeding-related complications. DSTAT is being studied in a Phase 2/3 trial to assess safety and efficacy in adults with acute lung injury with underlying COVID-19. A Phase 3 trial protocol to study DSTAT in acute myeloid leukemia has been agreed to with the
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are set forth in the Company's filings with the
CONTACT:
Investor Relations:
919 972-7115
ir@chimerix.com
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
Media:
858-717-2310
David.Schull@russopartnersllc.com
Source: Chimerix, Inc.